A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).

NCT00405080 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Nausea and Vomiting, Chemotherapy-Induced

Interventions

DRUG: GW679769 (Casopitant) oral tablets
DRUG: Rifampin oral capsules

Sponsor

GlaxoSmithKline